Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and effic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Can Respir J
Main Authors: Gong, Su-Gang, Wang, Lan, Pudasaini, Bigyan, Yuan, Ping, Jiang, Rong, Zhao, Qin-Hua, He, Jing, Zhang, Rui, Wu, Wen-hui, Liu, Jin-Ming, Zhou, Cai-cun
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5924990/
https://ncbi.nlm.nih.gov/pubmed/29849836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9836820
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados